<code id='6D72715168'></code><style id='6D72715168'></style>
    • <acronym id='6D72715168'></acronym>
      <center id='6D72715168'><center id='6D72715168'><tfoot id='6D72715168'></tfoot></center><abbr id='6D72715168'><dir id='6D72715168'><tfoot id='6D72715168'></tfoot><noframes id='6D72715168'>

    • <optgroup id='6D72715168'><strike id='6D72715168'><sup id='6D72715168'></sup></strike><code id='6D72715168'></code></optgroup>
        1. <b id='6D72715168'><label id='6D72715168'><select id='6D72715168'><dt id='6D72715168'><span id='6D72715168'></span></dt></select></label></b><u id='6D72715168'></u>
          <i id='6D72715168'><strike id='6D72715168'><tt id='6D72715168'><pre id='6D72715168'></pre></tt></strike></i>

          Home / Wikipedia / explore

          explore


          explore

          author:Wikipedia    Page View:3859
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In